"Published this week in the journal Nature, the work validates certain activating mutations in the FLT3 gene as targets for acute myeloid leukemia therapy — a critically important finding for developing drugs." This work used the PacBio's RS DNA sequencer.
" In collaboration with Pacific Biosciences, a Menlo Park, Calif. company, a new sequencing technology was adapted to more sensitively and precisely detect drug-resistant mutations. The team showed that in all eight cases, one or more of these mutations evolved at the time AC220-resistant disease developed."
I wish we had more clarity on the definition of the term --- " a new sequencing technology". Are they talking 3rd gen or some enhancement that we don't know about yet ??